



Landmark clinical results in treatment-resistant Binge Eating Disorder

July 2026

This presentation has been authorised for release by the Board of Entropy Neurodynamics Limited

ASX : ENP



Disclaimers

The information contained in this presentation (the "Presentation") has been prepared by Tryp Therapeutics Inc. ("Tryp" or the "Company") and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provided as at the date hereof and is subject to change without notice, (b) is for informational purposes only and does not purport to contain all information (including all material information) that may be necessary or desirable to fully and accurately evaluate the Company, (c) did not take into account the investment objectives, financial situation and particular needs of any particular investor, (d) is not to be considered as a recommendation by the Company that any person make an investment in Tryp, and (e) further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the Presentation. Those acting upon any information without advice do so entirely at their own risk.

This Presentation does not constitute an offer to sell or solicitation of an offer to buy any of the securities of Tryp. The sole purpose of this Presentation, in paper or electronic form, is strictly for information purposes. Neither Tryp, nor any of its current or proposed directors, officers, owners, managers, partners, consultants, employees, affiliates or representatives, make any warranty or representation, whether express or implied, or assume any legal liability or responsibility for any action taken in reliance upon this Presentation, or for the accuracy, completeness, fairness, or usefulness of any information disclosed in this Presentation.

Forward Looking Information. This Presentation contains forward looking statements with respect to Tryp. By their nature, forward looking statements involve risks and uncertainties and are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require Tryp to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that Tryp's assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally, forward looking statements can be identified by the use of terminology such as "anticipate", "will", "expect", "may", "continue", "could", "estimate", "forecast", "plan", "potential" and similar expressions. Forward looking statements contained in this Presentation may include, but are not limited to statements with respect to the outlook for the psilocybin industry and related industries; challenges and opportunities related to the psilocybin industry; the completion and timing of clinical studies; the ability of any patents resulting from Tryp's patent applications to protect the commercial prospects of its assets; the achievement, and the timing of, certain development milestones and the successful execution of Tryp's business strategy (including its business model and mission); the use and benefits of Tryp's products and services; demographic and market size/trends; forecasts of revenue and financial projections/growth potential; Tryp's ability to obtain marketing exclusivity for any of its approved drug products; anticipated capitalization, projected milestones and the go-forward management of Tryp; These forward looking statements are based on a number of assumptions which may prove to be incorrect including, but not limited to: general economic, market and business conditions, the outcome of research studies, the ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain sufficient capital on satisfactory terms, availability of equipment and supplies, changes in customer demand, the successful and timely implementation of capital projects, currency exchange rates and the impact of changes in applicable laws and regulations. The forward-looking statements contained in this Presentation are made as of the date hereof or the dates specifically referenced in this Presentation, where applicable. Except as required by law, Tryp undertakes no obligation to update publicly or to revise any forward-looking statements that are contained or incorporated in this Presentation. All forward looking statements contained in this Presentation are expressly qualified by this cautionary statement.

Third-Party Information. This Presentation includes market and industry data obtained from various publicly available sources and other sources believed by the Company to be reliable. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this Presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation or warranty, express or implied as to the accuracy of such information. No responsibility or liability is accepted for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this Presentation. Some numbers in this Presentation may not be exact or add consistently due to rounding.

Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this Presentation or any document supplied with this Presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Electronic Form. This Presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk, and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version that may be made available to you.

This Presentation and its contents are confidential and should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person without the prior written consent of the Company. The Company does not assume responsibility for liabilities, losses or damages suffered by the recipients of this Presentation or any other person as a result of the circulation, reproduction or use of this Presentation.

Psilocybin. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug. While the Company is focused on developing products using psilocybin, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances. The Company does not currently manufacture, store or otherwise handle psilocybin directly and will only do so through agents within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products that contain psilocybin or other psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding.

Adverse effects of psilocybin and its derivatives can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.



- Entropy Neurodynamics is a clinical-stage biotechnology company developing next-generation psychedelic medicine for neuropsychiatric disorders
- Entropy's proprietary IV-delivered psilocin therapy, TRP-8803, is designed to provide a rapid, precise, reversible and predictable treatment experience, that delivers significant benefits to both the physician and the patient compared to first-generation oral psilocybin therapy
- The Company is targeting high unmet medical needs, across neuropsychiatric conditions including binge eating disorder, irritable bowel syndrome, fibromyalgia, anxiety and depression
- Entropy's technology is designed to enable scalable, pharmaceutical-grade psychedelic therapies for mainstream clinical use

Corporate Overview




Corporate Snapshot

ASX code:	ENP
Shares on issue:	1.632Bn
Market capitalisation: (at \$0.034 per share)	AU\$55.5m
Cash at bank: (at 31 March 2026)	AU\$6.5m
Debt:	Nil

Board of Directors

Non-Executive Chairman	Mr. Herwig Janssen
Chief Executive Officer	Mr. Jason Carroll
Executive Director	Mr. Chris Ntoumenopoulos
Non-Executive Director	Dr. Daniel Tillett
Non-Executive Director	Mr. Gage Jull



Shareholders (at 03 July 2026)

Dr. William James Garner (<i>Co-founder</i>)	13.6%
Dr. Daniel Tillett (<i>NED</i>)	4.1%
Mr. Jason Carroll (<i>CEO</i>)	3.8%
Mr. Herwig Janssen (<i>Chair</i>)	2.3%
Mr. Chris Ntoumenopoulos (<i>ED</i>)	0.9%
Top 10: (change vs Q2)	42.7% (+1.9%)
Top 20:	50.9%
Top 100:	80.4%



Previous signal studies have laid a strong scientific foundation

TAM AU\$42.6Bn

Fibromyalgia (FM)



- Multi-Domain Improvement
- Pain · Sleep · Mood · Function

University of Michigan

TAM AU\$14.7Bn

Binge Eating Disorder (BED)



- Binge Episodes 10.8 → 0 by Week 6
- Depression Scores Halved

University of Florida

TAM AU\$88.2Bn

Irritable Bowel Syndrome (IBS)



- Clinically Meaningful, Durable Reduction
- Responders Sustain Benefit

Harvard University

Previous studies have delivered positive signals across three major conditions

TRP-8803 has been specifically designed to remove the barriers to therapy



TRP-8803 : A Precision approach in Neuropsychiatry


	IV-infused Psilocin	Oral Psilocybin *
Short treatment duration of 1-2 hours	✓	✗ ~8-10 hours
Quick onset of psychedelic state (~15 minutes)	✓	✗ 1-2 hours
Precision targeting of drug blood levels in patients	✓	✗ highly variable
Patient safety - quickly reversible in emergency	✓	✗
Strong IP positioning	✓	✗
Commercially scalable	✓	?

* Companies developing oral psilocybin include: Compass Pathways, Cybin, USONA amongst many others

Phase 2 TRP-8803 trial in treatment-resistant Binge-Eating Disorder (BED)



- **Overview:** Phase 2, open-label clinical trial conducted in collaboration with Swinburne University
- **Objective:** Evaluate the safety, tolerability and preliminary efficacy of TRP-8803
- **Therapy:** Proprietary precision-controlled IV psilocin (TRP-8803)
- **Cohort:** 12 chronic, treatment-resistant Binge Eating Disorder sufferers
- **Design:** Participants receive two IV infusions, 14 days apart, with psychological support
- **Primary endpoint:** Safety and tolerability
- **Key efficacy measures:** Changes in binge eating frequency, binge eating severity, anxiety and quality of life
- **Status:** Cohort 1 completed with positive topline results; study progressing through second cohort 2 next month





Landmark Clinical Trial Results with TRP-8803

World-first results highlight TRP-8803's potential as a treatment route

TRP-8803 delivered 50% remission in treatment-resistant Binge Eating Disorder and clinical improvement in 100% of patients

Clinical safety and efficacy results represent a historic milestone for the field of psychedelic medicine and marks the first clinical efficacy data globally for precision-controlled intravenous psilocin

Strength, control, consistency and multi-domain scale of outcomes achieved materially exceeded expectations and establish Entropy as a leader in psychedelic therapeutics

50%
**CLINICAL
REMISSION**

100%
**CLINICALLY
MEANINGFUL
IMPROVEMENT**

74%
**REDUCTION IN
WEEKLY BINGE
EATING EPISODES**



Topline results from treatment-resistant binge-eating-disorder

100% of patients achieved clinically meaningful BED symptom improvements

57% (8-point) reduction in Depression (PHQ-9)

50% of treatment-resistant BED patients achieved clinical remission (zero BED episodes)

63% improvement in satisfaction with life

74% reduction in binge eating episodes (from 2.6/week to 0.7/week at week 4)

Clinical Global Impression improvement of 33%

58% (6-point) reduction in Anxiety (GAD-7)

Final 12 patient study results expected Q4 CY26

Large, multi-domain therapeutic gains rarely seen in early-phase psychiatric trials

Strategic Significance



Cohort 1 represents a pivotal clinical milestone for Entropy. As the world's first efficacy data generated from precision-controlled, IV-psilocin, the study demonstrates that TRP-8803 delivers rapid, reproducible and clinically meaningful therapeutic benefit in patients with refractory BED.

- ✓ Validates Entropy's differentiated precision-controlled psychedelic platform
- ✓ Materially de-risks the TRP-8803 program to enter multiple new indications
- ✓ Strengthens regulatory and partnering positioning and establishes a robust foundation for expansion into additional neuropsychiatric indications
- ✓ EEG analysis has identified a robust mechanistic entropy biomarker signature during dosing – increasing the potential for developing true predictive outcomes of patient therapy


Combined with the DSMB's endorsement of the 60-minute infusion regimen, TRP-8803 is emerging as one of the most clinically practical and scalable psychedelic therapies under development globally.

Global Pharma chasing differentiated Phase 2 assets on minimal patient data



August 25, 2025

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin



AUGUST 25, 2025: AU\$1.75Bn transaction for a pharmaceutical small molecule, bretisilocin (at Phase 2a) is a very potent signal from the company considered to be the leading acquirer of new products in new therapeutic areas.

Bretisilocin in a rapid acting synthetic “small molecule” tryptamine with a single 40 patient MDD study.

BREAKING: Otsuka to Acquire Methylone Drug Developer Transcend in \$1.23B Deal



JUNE 13, 2026: AU\$1.8Bn (AU\$1Bn upfront) transaction from Otsuka Pharmaceuticals for Transcend Therapeutics. Founded in 2021, New York-based Transcend reported positive phase 2 data in 2025 for TSND-201, an MDMA analog.

65 patient placebo-controlled study showed 9.6 point improvement on CAPS-5 PTSD scale for TNSD-201 vs placebo (Day 64). Compared with Lykos' 8.9 point improvement after 126 days

Aggressive Absorption of Global Intellectual Property Portfolio rights



Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing and treatment of specific disease indications have been filed for all major global pharmaceutical markets

- Provisional patent filed in March 2021 (US 63/161,070) covering TRP-8803 (IV-infused Psilocin); converted to PCT filing March 2022; published September 22, 2022 **(Australian Patent Granted)**
- Provisional patent application covering the use of psilocybin and derivatives in the treatment of Binge Eating Disorder (BED) filed June 2022
- Provisional patent application for the treatment of fibromyalgia filed September 2022
- Provisional patent application for salt & co-formers of TRP-8803 filed September 2022
- Provisional patent for IBS filed January 2, 2023
- New patent family filed July 2025 (EEG-guided therapy)

Allens > Linklaters



Historical Milestones & Pending Catalysts

Milestone	Timing	Status
Completion of TRP-8803 Phase 1 study in healthy human volunteers (14)	H3CY24	✓
TRP-8802 Positive Fibromyalgia and BED Phase 2a interim data (University of Michigan & Florida)	H1CY24	✓
TRP-8803 BED Phase 2a BED trial commencement (in collaboration with Swinburne University)	H2CY25	✓
TRP-8803 Positive Topline data (Cohort 1) in Binge Eating Disorder	July CY26	✓
TRP-8803 64 patient multi-indication study announcement (Swinburne University)	July CY26	Imminent
TRP-8803 Interim data on Indication 1–8 (Multiple data announcements will be released as each indication is completed throughout the period through Q4CY26 to Q2CY2027)	Q4CY26– Q2CY27	Pending
TRP-8803 Final data (Cohort 1 & 2) in Binge Eating Disorder EEG – Biomarker predictive outcome signature presentation	Q4CY26– Q1CY27	Pending



CONTACT

Jason Carroll

Chief Executive Officer

jcarroll@tryptherapeutics.com

Website:

www.entropyneurodynamics.com

Henry Jordan

Six Degrees Investor Relations

henry.jordan@sdir.com.au

Socials:

X (Twitter) [@tryptherapeutic](https://twitter.com/tryptherapeutic)